Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S Komrokji, John F Seymour, Andrew W Roberts, Martha Wadleigh, L Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S Campbell, Ruben A Mesa
Blood | AMER SOC HEMATOLOGY | Published : 2015
This study was sponsored by S*Bio Pte Ltd, Singapore. No grant support was received. All views expressed in this article are those of the authors and not an official position of the funding institution.